Lasho T - Search Results

1

A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.

Mesa RA, Powell H, Lasho T, DeWald GW, McClure R, Tefferi A. Mesa RA, et al. Among authors: lasho t. Haematologica. 2006 Mar;91(3):415-6. Haematologica. 2006. PMID: 16531268

2

JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.

Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A. Mesa RA, et al. Among authors: lasho t. Leuk Res. 2006 Nov;30(11):1457-60. doi: 10.1016/j.leukres.2006.01.008. Epub 2006 Mar 23. Leuk Res. 2006. PMID: 16563504

3

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. Pardanani AD, et al. Among authors: lasho t. Blood. 2006 Nov 15;108(10):3472-6. doi: 10.1182/blood-2006-04-018879. Epub 2006 Jul 25. Blood. 2006. PMID: 16868251 Free article.

4

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.

Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C, Li CY, Tefferi A. Mesa RA, et al. Among authors: lasho t. Leukemia. 2007 Sep;21(9):1964-70. doi: 10.1038/sj.leu.2404816. Epub 2007 Jun 21. Leukemia. 2007. PMID: 17581608 Clinical Trial.

5

Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders.

Pardanani A, Lasho T, McClure R, Lacy M, Tefferi A. Pardanani A, et al. Among authors: lasho t. Blood. 2006 Jun 1;107(11):4572-3. doi: 10.1182/blood-2005-12-4988. Blood. 2006. PMID: 16717134 Free article. No abstract available.

6

Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.

Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, Ketterling RP, Hanson CA, Van Dyke DL, Tefferi A. Hussein K, et al. Among authors: lasho t. Eur J Haematol. 2009 Apr;82(4):255-9. doi: 10.1111/j.1600-0609.2009.01216.x. Epub 2008 Feb 10. Eur J Haematol. 2009. PMID: 19215287

7

Bortezomib therapy in myelofibrosis: a phase II clinical trial.

Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, Wu W, Tefferi A. Mesa RA, et al. Among authors: lasho t. Leukemia. 2008 Aug;22(8):1636-8. doi: 10.1038/leu.2008.32. Epub 2008 Feb 28. Leukemia. 2008. PMID: 18305559 Free PMC article. Clinical Trial. No abstract available.

8

5-Azacitidine has limited therapeutic activity in myelofibrosis.

Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, Wu W, Tefferi A. Mesa RA, et al. Among authors: lasho t. Leukemia. 2009 Jan;23(1):180-2. doi: 10.1038/leu.2008.136. Epub 2008 May 29. Leukemia. 2009. PMID: 18509350 Free PMC article. Clinical Trial. No abstract available.

9

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.

Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. Pardanani A, et al. Among authors: lasho t. Leukemia. 2010 Oct;24(10):1713-8. doi: 10.1038/leu.2010.163. Epub 2010 Aug 19. Leukemia. 2010. PMID: 20724988

10

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.

Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A. Pardanani A, et al. Among authors: lasho t. Leukemia. 2007 Aug;21(8):1658-68. doi: 10.1038/sj.leu.2404750. Epub 2007 May 31. Leukemia. 2007. PMID: 17541402

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

285 results

Search Page

Filters